K-numberK243403
Device nameBD Nexiva™ Closed IV Catheter System
ApplicantBecton Dickinson Infusion Therapy Systems, Inc.
Product codeFOZ
Device classClass II
Decision dateJul 25, 2025
DecisionSubstantially Equivalent
Regulation880.5200
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

The BD Nexiva™ Closed IV Catheter System is an over-the-needle, peripheral intravascular catheter intended for short-term use to sample blood, monitor blood pressure, or administer fluids (single-port) or to sample blood or administer fluids (dual-port). It incorporates a radiopaque polyurethane catheter with integrated extension tubing, a closed needle-free system with blood-containment design, and pre-attached needle-free connectors in some configurations.

Technological characteristics

The subject device is substantially equivalent to its predicate in fundamental technology: both are closed peripheral intravascular catheter systems with integrated extension sets, single or dual-port injection sites, and Instaflash™ needle technology. Component materials, catheter dimensions (18–24 GA, 0.56–1.75 inches), product configurations, and sterilization method (ethylene oxide) are identical. The only material modification is the stainless steel needle grade, which does not raise new safety or effectiveness questions.

Test standards cited

ISO 80369-7 (in place of previous ISO 594-1 and ISO 594-2 standards), ISO 11607-1, plus performance testing for Frequency Response, Kink Resistance, and Blood Fill Time.

Substantial equivalence argument

The subject device meets substantial equivalence because it maintains identical indications for use (with clarifying addition of "peripheral" and narrowing of dual-port IFU to exclude blood pressure monitoring), uses the same technological principles and component materials as the predicate, and demonstrates compliance with the same or updated consensus standards (ISO 80369-7). Performance testing confirms the device meets all predetermined acceptance criteria. The modifications (performance specification refinements and narrowed IFU scope) do not introduce new safety or effectiveness questions and remain within the predicate's intended clinical function.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →